Clinical trial
A Phase 3, Double-blind, Outpatient Crossover Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4 Diaminopyridine Phosphate) in Patients With Congenital Myasthenic Syndromes (CMS)
NCT02562066 is registered in ClinicalTrials.gov with Catalyst Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-blind, Outpatient Crossover Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4 Diaminopyridine Phosphate) in Patients With Congenital Myasthenic Syndromes (CMS)
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- October 31, 2019
- Enrollment
- 20 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.